[{"NetIncomeLoss_2_Q2_USD":-35187000.0,"EquityMethodInvestments_0_Q2_USD":4147000.0,"DeferredRentCreditCurrent_0_Q2_USD":377000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":6874000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":13277000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":41945058.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":41867089.0,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1_Q2_USD":-0.47,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2_Q2_USD":-0.84,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":8265000.0,"OperatingLeasesRentExpenseNet_1_Q2_USD":400000.0,"OperatingLeasesRentExpenseNet_2_Q2_USD":800000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-44000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-68488000.0,"Depreciation_2_Q2_USD":144000.0,"AssetsCurrent_0_Q2_USD":293796000.0,"PrepaidExpenseAndOtherAssets_0_Q2_USD":2563000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":5556631.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":78000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-44000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_2_Q2_USD":84000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-44000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":226666000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_Q2_USD":-35231000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":795000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":12947000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":22674000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-688000.0,"OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0_Q2_USD":1297000.0,"CommonStockValue_0_Q2_USD":4000.0,"InvestmentIncomeNet_1_Q2_USD":157000.0,"InvestmentIncomeNet_2_Q2_USD":1093000.0,"IncreaseDecreaseInOtherCurrentAssets_2_Q2_USD":281000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":84000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q2_USD":291200000.0,"OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_0_Q2_USD":674000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":-19893000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":-35187000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-19937000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-35231000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-1745000.0,"OtherAssetsNoncurrent_0_Q2_USD":1440000.0,"Liabilities_0_Q2_USD":10146000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q2_USD":-19937000.0,"CommonStockSharesIssued_0_Q2_shares":43016501.0,"Assets_0_Q2_USD":301020000.0,"PaymentsToAcquireEquityMethodInvestments_2_Q2_USD":3500000.0,"IncomeLossFromEquityMethodInvestments_1_Q2_USD":-229000.0,"IncomeLossFromEquityMethodInvestments_2_Q2_USD":-329000.0,"OperatingLeasesFutureMinimumPaymentsDueInTwoYears_0_Q2_USD":1372000.0,"OperatingLeasesFutureMinimumPaymentsDueInFourYears_0_Q2_USD":135000.0,"MarketableSecuritiesUnrealizedGainLoss_2_Q2_USD":44000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-32557000.0,"LiabilitiesCurrent_0_Q2_USD":9551000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q2_USD":-100961000.0,"AccountsPayableCurrent_0_Q2_USD":909000.0,"NonoperatingIncomeExpense_1_Q2_USD":157000.0,"NonoperatingIncomeExpense_2_Q2_USD":1093000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":227231000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":84000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":323000.0,"AdditionalPaidInCapital_0_Q2_USD":399130000.0,"NumberOfOperatingSegments_2_Q2_segment":1.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":1072000.0,"NetIncomeLoss_1_Q2_USD":-19893000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":64567000.0,"IncreaseDecreaseInDeferredLiabilities_2_Q2_USD":-180000.0,"RestrictedCashNoncurrent_0_Q2_USD":565000.0,"AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_2_Q2_USD":3949000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-44000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-44000.0,"ShareBasedCompensation_2_Q2_USD":3949000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-1146000.0,"CommonStockSharesAuthorized_0_Q2_shares":150000000.0,"OperatingIncomeLoss_1_Q2_USD":-19821000.0,"OperatingIncomeLoss_2_Q2_USD":-35951000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":301020000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":2105000.0,"OperatingExpenses_1_Q2_USD":19821000.0,"OperatingExpenses_2_Q2_USD":35951000.0,"ProfitLoss_2_Q2_USD":-35187000.0,"StockholdersEquity_0_Q2_USD":290874000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":421000.0,"DeferredRentCreditNoncurrent_0_Q2_USD":595000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-108216000.0,"MarketableSecurities_0_Q2_USD":64567000.0,"AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_1_Q2_USD":2599000.0,"CommonStockSharesOutstanding_0_Q2_shares":43016501.0,"OperatingLeasesFutureMinimumPaymentsDue_0_Q2_USD":3478000.0,"Ticker":"SWTX","CIK":"1773427","name":"SPRINGWORKS THERAPEUTICS, INC.","OfficialName":"SpringWorks Therapeutics Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"2504354261.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200812"}]